Journals / Anadolu Kardiyoloji Dergisi / 2010 / Cilt: 10 - Sayı: 1

Kosovo’da kardiyoloji servisine başvuran hastalarda atriyal fibrilasyonun komorbiditeleri ve takibi-Tek merkezli çalışma

Management and comorbidities of atrial fibrillation in patients admitted in cardiology service in Kosovo-a single-center study

Pages
36–40
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Multivariate analysis showed that the under-prescription of OAC therapy in patients with AF was independently associated with elder age (OR=0.916, 95%CI 0.891-0.942, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Atrial fibrillation (AF) is the most important risk factor for ischemic stroke.
📊
Key Findings & Data:Anticoagulation therapy can substantially decrease the risk of stroke in patients with AF.
💡
Conclusion & Impact:Multivariate analysis showed that the under-prescription of OAC therapy in patients with AF was independently associated with elder age (OR=0.916, 95%CI 0.891-0.942, p
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Atrial fibrillation (AF) is the most important risk factor for ischemic stroke. Anticoagulation therapy can substantially decrease the risk of stroke in patients with AF. The aim of our study was to investigate the patient’s comorbidities and management of patients with AF on the discharge. Methods: From 5382 consecutive patients admitted in our institution between January 2005 and March 2008, 525 (mean age 66.4±11.4 years, 53.3% male) had AF upon discharge, who were included in this retrospective study. Patients were divided in two groups according to prescription of anticoagulation therapy at discharge. Continuous data were compared between groups using a two-tailed unpaired Student t test. Discrete variables were compared using Chi-square test or Fisher’s exact probability test as appropriate. Logistic regression analysis was used to identify the independent clinical and echocardiographic predictors of prescribing oral anticoagulation therapy. Results: Associated comorbidities of AF in our patients were: ischemic heart disease (21.4%), hypertensive heart disease (27.44%), valvular heart disease (17.4%), congestive heart failure (47%), chronic obstructive pulmonary disease (6.7%), and diabetes 14.3%). Of 525 patients 76% were discharged on beta-blockers, 67% on angiotensin converting enzyme inhibitors, 23% on digoxin, 16% on calcium antagonists, 67% on diuretics, 72% on aspirin, and 27% on oral anticoagulant (OAC) therapy, 11% were with both antithrombotics. Multivariate analysis showed that the under-prescription of OAC therapy in patients with AF was independently associated with elder age (OR=0.916, 95%CI 0.891-0.942, p

Özet

Amaç: Atriyal fibrilasyon (AF) iskemik inmenin en önemli risk faktörüdür. Antikoagülasyon tedavisi atriyal fibrilasyonlu hastalarda inme riskini büyük oranda azaltabilir. Bizim çalışmamızın amacı, taburcu olan AF’li hastaların takibi ve hastaların komorbiditesini araştırmak idi. Yöntemler: Ocak 2005 ve Mart 2008 tarihleri arasında kurumumuza başvuran 5382 ardışık hastadan, bu retrospektif çalışmaya dahil edilen 525’i (ortalama yaş 66.4±11.4 yaş, %53.3 erkek) taburcu edilirken atriyal fibrilasyonlu idi. Hastalar taburcu olurken antikoagülasyon tedavi reçetesine göre iki gruba ayrıldı. Eşleştirilmemiş Student t testi kullanılarak sürekli veriler gruplar arasında karşılaştırıldı. Uygunluklarına göre kategorik değişkenler, Ki-kare testi ya da Fisher’in kesin olasılık testi kullanılarak karşılaştırıldı. Oral antikoagülasyon tedavisinin reçetelenmesinin bağımsız klinik ve ekokardiyografik belirleyicilerini tanımlamak için lojistik regresyon analizi kullanıldı. Bulgular: Hastalarımızda atriyal fibrilasyonla ilgili komorbiditeler: İskemik kalp hastalığı (%21.4), hipertansif kalp hastalığı (%27.4), valvüler kalp hastalığı (%17.4), kongestif kalp yetersizliği (%47), kronik obstrüktif pulmoner hastalık (%6.7) ve diyabettir (%14.3). Hastların %76'sı beta-blokerlerle, %67 anjiyotensin dönüştürücü enzim inhibitörlerle, %23 digoksinle, %16 kalsiyum antagonistleri ile %67 diüretik ilaçlarla, ve %72 aspirinle ve 27% oral antikoagülasyon tedavisi (OAK) ile taburcu edildi, %11 ise her iki antitrombotiği alıyordu. Çok değişkenli analiz atriyal fibrilasyonlu hastalarda OAK tedavinin daha az reçetelenmesinin ileri yaş (OR=0.916, %95GA 0.891-0.942, p

🔖

Cite This Article

QERKINI, G., BUJUPI, L., SHABANI, D., BAJRAKTARI, G., ELEZI, S. (2022). Kosovo’da kardiyoloji servisine başvuran hastalarda atriyal fibrilasyonun komorbiditeleri ve takibi-Tek merkezli çalışma. Anadolu Kardiyoloji Dergisi, Cilt: 10 - Sayı: 1, 36–40. https://ajindex.com/articles/436819

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991
  2. PMid:1866765 2. Cerebral Embolism Task Force. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol 1989
  3. PMid:2662950 3. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996
  4. doi:10.1016/S0140-6736(96)03487-3 4. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991
  5. PMid:1860198 5. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo- controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989
  6. doi:10.1016/S0140-6736(89)91200-2 6. Andersen KK, Olsen TS. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22,179 patients with ischemic stroke. Stroke 2007
  7. doi:10.1161/01.STR.0000254622.52483.03 PMid:17194876 7. Albers GW, Yim JM, Belew KM, Bittar N, Hattemer CR, Phillips BG, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996
  8. doi:10.1001/archinte.156.20.2311 PMid:8911237 8. Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000
  9. doi:10.1136/bmj.320.7246.1380 PMid:10818030 PMCid:27382 9. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995
  10. doi:10.1001/archinte.155.3.277 PMid:7832599 10. Monte S, Macchia A, Pellegrini F, Romero M, Lepore V, D'Ettorre A, et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J 2006
  11. doi:10.1093/eurheartj/ehl208 PMid:16935869 11. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive w